Tricyclic Neuroleptics: Structure-Activity Relationships

  • J. Schmutz
  • C. W. Picard
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 55 / 1)


In recent years, several excellent reviews dealing with the structure-activity relationships of the tricyclic neuroleptics have appeared (Janssen, 1973; Zirkle and Kaiser, 1974; Gschwend, 1974; Janssen and van Bever, 1975). In particular, the detailed review of Zirkle and Kaiser (1974) will serve as a basis for our discussion. The latter authors have relied largely on the conditioned avoidance response (CAR) test in rats as a pharmacological measure of neuroleptic activity. Other authors have used central depressant activities, e.g. depression of locomotor activity in mice or the rotating rod test which is a measure of the degree of motor incoordination in mice.


Central Ring Neuroleptic Drug Piperazine Ring Neuroleptic Agent Basic Side Chain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aizenshtat, Z., Klein, E., Weiler-Feilchenfeld, H., Bergmann, E.D.: Conformational studies on xanthene, thioxanthene and acridan. Isr. J. Chem. 10, 753–763 (1972)Google Scholar
  2. Angrist, B., Rotrosen, J., Aronson, M., Gershon, S.: A morphanthridine derivative in schizophrenic patients. Lack of extrapyramidal symptoms. Curr. Therap. Res. 20, 94–98 (1976)Google Scholar
  3. Aroney, M.J., Cleaver, G., Le Fèvre, R.J.W., Pierens, R.K.: Molecular polarisability. The conformations as solutes of 9, 10-dihydroanthracene, anthrone, and xanthone. J. Chem. Soc. (B) 1971, 82–85Google Scholar
  4. Aschwanden, W., Kyburz, E., Schönholzer, P.: Stereospezifität der neuroleptischen Wirkung und Chiralität von (+)-3- {2-[4-(8-Fluor-2-methyl-10, 11-dihydrodibenzo[b,f]thiepin- 10-yl)-l-piperazinyl]-äthyl}-2-oxazolidinon. Helv. Chim. Acta 59, 1245–1252 (1976)PubMedGoogle Scholar
  5. Barbe, J., Blanc, A., Hurwic, J.: Etude conformationnelle des phénothiazines N-substituées. Application aux relations structure-activités. C.R. Acad. Sci. (Paris) 277, 1071–1074 (1973)Google Scholar
  6. Barbe, J., Chauvet-Monges, A.-M.: Résonance magnétique nucléaire du proton à 250 MHz et conformations de la chaîne alkylamine de quelques phénothiazines-2,10 substituéees. C.R. Acad. Sci. (Paris) 279, 935–938 (1974)Google Scholar
  7. Barry, H.III., Steenberg, M.L., Manian, A.A., Buckley, J.P.: Effects of chlorpromazine and three metabolites on behavioral responses in rats. Psychopharmacologia 34, 351–360 (1974)PubMedGoogle Scholar
  8. Bickel, M.H., Brodie, B.B.: Structure and antidepressant activity of imipramine analogues. Int. J. Neuropharmacol. 3, 611–621 (1964)PubMedGoogle Scholar
  9. Bird, P.H., Bruderlein, F.T., Humber, L.G.: Crystallographic studies on neuroleptics of the benzocycloheptapyridoisoquinoline series. The crystal structure of butaclamol hydro-bromide and the absolute configuration and crystal structure of dexclamol hydrobromide. Can. J. Chem. 54, 2715–2722 (1976)Google Scholar
  10. Bossle, P.C., Ferguson, C.P., Sultan, W.E., Lennox, W.J., Dudley, G.E., Rea, T.H., Miller, J.I.: Synthesis and biological activity of new 2-substituted analogs of fluphenazine. J. Med. Chem. 19, 370–373 (1976)PubMedGoogle Scholar
  11. Bruderlein, F.T., Humber, L.G., Voith, K.: Neuroleptic agents of the benzocycloheptapyri-doisoquinoline series. I. Syntheses and stereochemical and structural requirements for activity of butaclamol and related compounds. J. Med. Chem. 18, 185–188 (1975)PubMedGoogle Scholar
  12. Brune, G.G., Kohl, H.H., Steiner, W.G., Himwich, H.E.: Relevance of the N,N-dimethyl configuration to the pharmacological action of chlorpromazine. Biochem. Pharmacol. 12, 679–685 (1963)PubMedGoogle Scholar
  13. Bürki, H.R.: Correlation between 3H-haloperidol binding in the striatum and brain amine metabolism in the rat after treatment with neuroleptics. Life Sci. 23, 437–442 (1978)PubMedGoogle Scholar
  14. Bürki, H.R., Sayers, A.C., Ruch, W., Asper, H.: Effects of clozapine and other dibenzo-epines on central dopaminergic and cholinergic systems. Structure-activity relationships. Arzneim. Forsch. 27, (II), 1561–1565 (1977)Google Scholar
  15. Bürki, H.R., Fischer, R., Hunziker, F., Künzle, F., Petcher, T.J., Schmutz, J., Weber, H.P., White, T.G.: Dibenzo-epines: effect of the basic side-chain on neuroleptic activity. Eur. J. Med. Chem. 13, 479–485 (1978)Google Scholar
  16. Bürki, H.R., Fischer, R., Hunziker, F., Künzle, F., Petcher, T.J., Schmutz, J., Weber, H.P., White, T.G.: Dibenzo-epines: Effect of the basic side chain on neuroleptic activity. To be publishedGoogle Scholar
  17. Burt, D.R., Enna, S.J., Creese, I., Snyder, S.H.: Dopamine receptor binding in the corpus striatum of mammalian brain. Proc. Natl. Acad. Sci. USA 72, 4655–4659 (1975)PubMedGoogle Scholar
  18. Burt, D.R., Creese, I., Snyder, S.H.: Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol. Pharmacol. 12, 800–812 (1976)PubMedGoogle Scholar
  19. Carnmalm, B., Johansson, L., Rämsby, S., Stjernström, N.E., Ross, S.B., Ogren, S.-O.: Stereoselective effects of the potentially neuroleptic rigid spiro-amines. Nature 263, 519–520(1976)PubMedGoogle Scholar
  20. Červená, I., Metyšová, J., Svátek, E., Kakáč, B., Holubek, J., Hrubantová, M., Protiva, M.: Potent neuroleptics with prolonged activity and diminished toxicity; 7,8-dihalogeno-10-piperazinodibenzo[b,f]thiepins. Coll. Czech. Chem. Commun. 41, 881–905 (1976)Google Scholar
  21. Chu, S.S.C., Chung, B.: The crystal structure of (+)-cis-9-(3-dimethylaminopropyl)-10-methyl-2-(trifluoromethyl)-9,10-dihydroanthracene hydrochloride monohydrate, SKFd-28175, acetone solvate. Acta Cryst. B 32, 836–842 (1976)Google Scholar
  22. Corral, C., Lissavetzky, J., Madronero, R.: Analogues of antipsychotic phenothiazines. 10-(2-N′,N′-disubstituted hydrazinoethyl)phenothiazines. Eur. J. Med. Chem. 13, 389–391 (1978)Google Scholar
  23. Coscia, L., Causa, P., Giuliani, E.: New tricyclic enamine derivatives with CNS-depressant properties. Arzneim. Forsch. 25, 1261–1265 (1975 a)Google Scholar
  24. Coscia, L., Causa, P., Giuliani, E., Nunziata, A.: Pharmacological properties of new neuroleptic compounds. Arzneim. Forsch. 25, 1436–1442 (1975 b)Google Scholar
  25. Cosulich, D.B., Lovell, F.M.: The X-ray structure of loxapine {2-chloro-11-(4-methyl-l-piperazinyl)dibenz[b,f][l,4]oxazepine} and amoxapine {2-chloro-11-(l-piperazinyl)di-benz[b,f][l,4]oxazepine}. Acta Cryst. B 33, 1147–1154 (1977)Google Scholar
  26. Coubeils, J.L., Pullman, B.: Molecular orbital study of the conformational properties of phenothiazines. Theor. Chim. Acta (Berl.) 24, 35–41 (1972)Google Scholar
  27. Coupet, J., Szucs, V.A., Greenblatt, E.N.: The effects of 2-chloro-11-(4-methyl-piperazinyl)-di-benz[b,f][l,4]oxazepine (loxapine) and its derivatives on the dopamine-sensitive adenylate cyclase of rat striatal homogenates. Brain Res. 116, 177–180 (1976)PubMedGoogle Scholar
  28. Courvoisier, S., Ducrot, R., Fournel, J., Julou, L.: Propriétés pharmacodynamiques générales de la lévomépromazine. C.R. Soc. Biol. (Paris) 151, 1378–1382 (1957)Google Scholar
  29. Creese, I., Burt, D.R., Snyder, S.H.: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481–483 (1976)PubMedGoogle Scholar
  30. Creese, I., Manian, A.A., Prosser, R.D., Snyder, S.H.: 3H-Haloperidol binding to dopamine receptors in rat corpus striatum: influence of chlorpromazine metabolites and derivatives. Eur. J. Pharmacol. 47, 291–296 (1978)PubMedGoogle Scholar
  31. Crow, T.J., Johnstone, E.C.: Stereochemical specificity in the antipsychotic effects of flupen-thixol in man. Br. J. Pharmacol. 59, p. 466 (1977)Google Scholar
  32. De Paulis, T., Kelder, D., Ross, S.B.: On the topology of the norepinephrine transport carrier in rat hypothalamus. The site of action of tricyclic uptake inhibitors. Mol. Pharmacol. 14, 596–606 (1978 a)PubMedGoogle Scholar
  33. De Paulis, T., Liljefors, T.: Inhibition of amine uptake, conformations and inversion barriers of 5H-dibenzo[a,d]eycloheptene derivatives. A 1H-DNMR study. Eur. J. Med. Chem. 13, 327–335 (1978 b)Google Scholar
  34. Ebnöther, A., Jucker, E., Stoll, A.: Atropisomerie in der Dibenzo[a,d]cyclohepten-Reihe. Helv. Chim. Acta 48, 1237–1249 (1965)Google Scholar
  35. Enna, S.J., Bennett, J.P., Burt, D.R., Creese, I., Snyder, S.H.: Stereospecificity of interaction of neuroleptic drugs with neurotransmitters and correlation with clinical potency. Nature 263, 338–341 (1976)PubMedGoogle Scholar
  36. Feinberg, A.P., Snyder, S.H.: Phenothiazine drugs: structure-activity explained by a conformation that mimics dopamine. Proc. Natl. Acad. Sci. USA 72, 1899–1903 (1975)PubMedGoogle Scholar
  37. Fenner, H.: Structure-activity relationship in the field of phenothiazine drugs. Pharmakopsych. Neuro-Psychopharmakol. 3, 332–339 (1970)Google Scholar
  38. Fog, R.L., Randrup, A., Pakkenberg, H.: Neuroleptic action of quaternary chlorpromazine and related drugs injected into various brain areas in rats. Psychopharmacologia 12, 428–432 (1968)PubMedGoogle Scholar
  39. Fouché, J., Combrisson, S.: Étude conformationnelle par RMN des composés neuroleptiques dérivés du dibenzo[a,d]cycloheptène. Comparaison avec les neuroleptiques dérivés de la phénothiazine et du thioxanthène. Bull. Soc. Chim. Fr. 1973, 1693–1698Google Scholar
  40. Fowler, P.J., Zirkle, CL., Macko, E., Kaiser, C., Sarau, H., Tedeschi, D.H.: Pharmacological evaluation of clomacran, a new potent psychotropic agent. Arzneim. Forsch. 27 (I), 866–872 (1977 a)Google Scholar
  41. Fowler, P.J., Zirkle, CL., Macko, E., Setler, P.E., Sarau, H.M., Misher, A., Tedeschi, D.H.: Fluotracen: a tricyclic compound with the combined properties of antidepressants and antipsychotics in animals. Arzneim. Forsch. 27 (II), 1589–1595 (1977b)Google Scholar
  42. Gallant, D.M., Bishop, M.P., Guerrero-Figueroa, R.: CL-67,772: A preliminary evaluation of a potential antidepressant compound: animal and human correlations. Curr. Ther. Res. 13, 364–368 (1971)PubMedGoogle Scholar
  43. Gordon, M., Cook, L., Tedeschi, D.H., Tedeschi, R.E.: Some structure-activity relationships in the phenothiazines. Arzneim. Forsch. 13, 318–320 (1963)Google Scholar
  44. Gravem, A., Engstrand, E., Guleng, R.J.: Cis(Z)-clopenthixol and clopenthixol (Sordinol) in chronic psychotic patients. Acta Psychiatr. Scand. 58, 384–388 (1978)PubMedGoogle Scholar
  45. Greenblatt, E.N., Lippa, A.S., Osterberg, A.C.: The neuropharmacological actions of amox-apine. Arch. Int. Pharmacodyn. Ther. 233, 107–135 (1978)PubMedGoogle Scholar
  46. Grol, C.J., Rollema, H.: Synthesis and neuroleptic activity of isomeric thieno[l,4]benzo-thiazines. J. Med. Chem. 18, 857–861 (1975)PubMedGoogle Scholar
  47. Gschwend, H.W.: Chemical approaches to the development of neuroleptics. In: Industrial Pharmacology. Vol. I: Neuroleptics. Fielding, S., Lal, H. (eds.). Mount Kisco (N.Y.): Fu-tura 1974, pp. 1–51Google Scholar
  48. Häuser, D., Closse, A.: 3H-Clozapine binding to rat brain membranes. Life Sci. 23, 557–562 (1978)PubMedGoogle Scholar
  49. Horn, A.S., Post, M.L., Kennard, O.: Dopamine receptor blockade and the neuroleptics, a crystallographic study. J. Pharm. Pharmacol. 27, 553–563 (1975)PubMedGoogle Scholar
  50. Howell, CF., Ramirez, P., Hardy, R.A.: Tranquilizing 11-(4-piperidyl)dibenz[b,f][l,4]-ox-azepines and -thiazepines. U.S. Patent 3,501,483; Chem. Abs. 72, 132813 (1970)Google Scholar
  51. Humber, L.G., Bruderlein, F.T.: Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. A hypothesis on their mode of interaction with the central dopamine receptor. Mol. Pharmacol. 11, 833–840 (1975)PubMedGoogle Scholar
  52. Humber, L.G., Sideridis, N., Asselin, A.A., Bruderlein, F.T.: Neuroleptics related to butacla-mol. An investigation of the effects of chlorine substituents on the aromatic rings. J. Med. Chem. 21, 1225–1231 (1978)PubMedGoogle Scholar
  53. Iversen, L.L., Horn, A.S., Miller, R.J.: Structure-activity relationships for interactions of agonist and antagonist drugs with dopamine-stimulated adenylate cyclase of rat brain — a model for CNS dopamine receptors? In: Antipsychotic Drugs, Pharmacodynamics and Pharmacokinetics. Sedvall, G., Uvnäs, B., Zottermann, Y. (eds.). Oxford, New York: Pergamon 1976 a, pp. 285–303Google Scholar
  54. Iversen, L.L., Rogawski, M.A., Miller, R.J.: Comparison of the effects of neuroleptic drugs on pre- and postsynaptic dopaminergic mechanisms in the rat striatum. Mol. Pharmacol. 12, 251–262 (1976b)PubMedGoogle Scholar
  55. Janssen, P.A.J.: Structure-activity relationship (SAR) and drug design as illustrated with neuroleptic agents. In: International Encyclopedia of Pharmacology and Therapeutics. Peters, G. (ed.), Section 5: Structure Activity Relationship. Cavallito, C.J. (ed.). Oxford, New York: Pergamon 1973, pp. 37–73Google Scholar
  56. Janssen, P.A.J., van Bever, W.F.M.: Advances in the research for improved neuroleptic drugs. In: Current Developments in Psychopharmacology. Essman, W.B., Valzelli, L. (eds.). New York: Spectrum 1975, Vol. 2, pp. 167–184Google Scholar
  57. Janssen, P.A.J., Niemegeers, C.J.E., Schellekens, K.H.L.: Is it possible to predict the clinical effects of neuroleptic drugs from animal data? Part I: Neuroleptic activity spectra for rats. Arzneim. Forsch. 15, 104–117 (1965)Google Scholar
  58. Janssen, P.A.J., Niemegeers, C.J.E., Schellekens, K.H.L., Lenaerts, F.M.: An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine- or apomorphine-induced “chewing” and “agitation” in rats. Arzneim. Forsch. 17, 841–854 (1967)Google Scholar
  59. Jaunin, A., Petcher, T.J., Weber, H.P.: Conformations of some semi-rigid neuroleptic drugs. Part 2: Crystal structures of racemic and of (+)-(S)-octoclothepin{2-chloro-10, 11-dihydro-11-(4-methylpiperazin-l-yl)dibenzo[b,f]thiepin} and the absolute configuration of the latter. J. Chem. Soc. [Perkin II] 1977, 186–190Google Scholar
  60. Jílek, J.O., Šindelář, K., Rajšner, M., Dlabač, A., Metyšová, J., Votava, Z., Pomykáček, J., Protiva, M.: Noncataleptic potential neuroleptics; 2-halogeno-10-piperazindibenzo[b,f]-thiepins. Coll. Czech. Chem. Commun. 40, 2887–2904 (1975)Google Scholar
  61. Julou, L., Ducrot, R., Fouche, J.: Etude de quelques relations entre la structure chimique et l’activité neuroleptique. In: Convegno di Aggiornamento in Psicofarmacologia (Milano, 6–7 Nov. 1965). Atti Convegni Farmitalia. Torino: Edizione Minerva Medica 1966, pp. 20–54Google Scholar
  62. Kaiser, C., Pavloff, A.M., Garvey, E., Fowler, P.J., Tedeschi, D.H., Zirkle, C.L.: Effects of structure upon neuropharmacological activity of some chlorpromazine analogs of the di-phenylmethane type. J. Med. Chem. 15, 665–673 (1972)PubMedGoogle Scholar
  63. Kaiser, C., Fowler, P.J., Tedeschi, D.H., Lester, B.M., Garvey, E., Zirkle, C.L.: Synthesis and neuropharmacological activity of some piperidylidene derivatives of thioxanthenes, xan-thenes, dibenzoxepines, and acridans. J. Med. Chem. 17, 57–62 (1974 a)PubMedGoogle Scholar
  64. Kaiser, C., Warren, R.J., Zirkle, C.L.: Assignment of isomeric aminoalkylidene derivatives of xanthenes and thioxanthenes with neuropharmacological activity. J. Med. Chem. 17, 131–133 (1974b)PubMedGoogle Scholar
  65. Karobath, M.E.: Dopamin-Rezeptor-Blockade, ein möglicher Wirkungsmechanismus antipsychotisch wirksamer Pharmaka. Pharmakopsychatr. 8, 151–161 (1975)Google Scholar
  66. Koch, M.H.J.: The conformation of neuroleptic drugs. Mol. Pharmacol. 10, 425–437 (1974)PubMedGoogle Scholar
  67. Koch, M.H.J., Evrard, G.: 4-{2-(Methylthio)dibenzo[b,f]thiepin-11-yl}-l-piperazinylpropanol hemihydrate (oxyprothepine). Acta Cryst. B 30, 2925–2928 (1974)Google Scholar
  68. Kopicová, Z., Metyšová, J., Protiva, M.: Neuroleptics with protracted action; 3-fluoro derivatives of methiothepin and oxyprothepin and their 2-fluoro analogues. Coll. Czech. Chem. Commun. 40, 3519–3529 (1975)Google Scholar
  69. Laduron, P.: Limiting factors in the antagonism of neuroleptics on dopamine-sensitive adenylate cyclase. J. Pharm. Pharmacol. 28, 250–251 (1976)PubMedGoogle Scholar
  70. Leysen, J.E., Gommeren, W., Laduron, P.M.: Spiperone: A ligand of choice for neuroleptic receptors. I. Kinetic and characteristics of in vitro binding. Biochem. Pharmacol. 27, 307–316 (1978)PubMedGoogle Scholar
  71. Lippmann, W., Pugsley, T., Merker, J.: Effect of butaclamol and its enantiomers upon striatal homovanillic acid and adenyl cyclase of olfactory tubercle in rats. Life Sci. 16, 213–224 (1975)PubMedGoogle Scholar
  72. McDowell, J.J.H.: The molecular structures of phenothiazine derivatives. Adv. Biochem. Psy-chopharmacol. 9, 33–54 (1974)Google Scholar
  73. Mercier, M.J., Dumont, P.A.: Influence of the electron-donating properties on the psychotropic activity of phenothiazine derivatives. J. Pharm. Pharmacol. 24, 706–712 (1972)PubMedGoogle Scholar
  74. Metyš, J., Metyšová, J.: Pharmacological properties of the potential neuroleptic drug pera-thiepine. II. Action on the autonomic nervous system and other pharmacological effects. Activ. Nerv. Sup. (Praha) 8, 389–390 (1966)Google Scholar
  75. Metyšová, J., Protiva, M.: Stereospecificity of neuroleptic effects in the 10-piperazino-10, 11-dihydrodibenzo[b,f]thiepin series. Activitas nervosa superior (Praha) 17, 218–219 (1975)Google Scholar
  76. Michaelis, W., Gauch, R.: Intramolekulare Beweglichkeit eines Dibenzo[b,f]-l,4-thiazepin-5-oxids. Helv. Chim. Acta 52, 2486–2491 (1969)Google Scholar
  77. Miller, R.J., Horn, A.S., Iversen, L.L.: The action of neuroleptic drugs on dopamine-stimulated adenosine cyclic 3′,5′-monophosphate production in rat neostriatum and limbic forebrain. Mol. Pharmacol. 10, 759–766 (1974)Google Scholar
  78. Miller, R.J., Horn, A.S., Iversen, L.L.: Effect of butaclamol on dopamine-sensitive adenylate cyclase in the rat striatum. J. Pharm. Pharmacol. 27, 212–213 (1975)PubMedGoogle Scholar
  79. Miller, R.J., Hiley, C.R.: Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines. Naunyn-Schmiedebergs Arch. Pharmacol. 292, 289–293 (1976)Google Scholar
  80. Moereels, H., Tollenaere, J.P.: A comparison between the conformation of dexclamol and the tricyclic and butyrophenone type dopamine antagonists. Life Sci. 23, 459–464 (1978)PubMedGoogle Scholar
  81. Møller-Nielsen, I., Pedersen, V., Nymark, M., Frank, K.F., Boek, V., Fjalland, B., Christensen, A. V.: The comparative pharmacology of flupenthixol and some reference neuroleptics. Acta Pharmacol. Toxicol. 33, 353–362 (1973)Google Scholar
  82. Møller-Nielsen, I., Boek, V., Christensen, A.V., Danneskiold-Samsøe, P., Hyttel, J., Langeland, J., Pedersen, V., Svendsen, O.: The pharmacology of a new potent, long-acting neuroleptic, piflutixol. Acta Pharmacol. Toxicol. 41, 369–383 (1977)Google Scholar
  83. Muren, J.F., Muren, B.M.: Thioxanthene psychopharmacological agents. I. 9-(3-Aminopro-pyl)-thioxanthene-2-sulfonamides. J. Med. Chem. 13, 14–16 (1970)PubMedGoogle Scholar
  84. Ögren, S.O., Hall, H., Köhler, C.: Studies on the stereoselective dopamine receptor blockade in the rat brain by rigid spiro amines. Life Sci. 23, 1769–1774 (1978)PubMedGoogle Scholar
  85. Pelz, K., Jirkovsky, L, Adlerová, E., Metysovâ, J., Protiva, M.: Über die in 8-Stellung durch die Methyl-, tert. Butyl-, Methoxy-, Methylthio- und Methansulfonylgruppe substituierten 10-(4-Methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin-Derivate. Coll. Czech. Chem. Commun. 33, 1895–1910 (1968)Google Scholar
  86. Petcher, T.J., Schmutz, J., Weber, H.P., White, T.G.: Chirality of (+)-octoclothepin, a stereo-specific neuroleptic agent. Experientia 31, 1389–1390 (1975)PubMedGoogle Scholar
  87. Petcher, T.J., Weber, H.P.: Conformations of some semi-rigid neuroleptic drugs. Part 1: Crystal structures of loxapine, clozapine, and HUF-2046 monohydrate {2-chloro-11-(4-methyl-piperazin-1 -yl)dibenzo[b,f][1,4]oxazepine, 8-chloro-11 -(4-methylpiperazin-1 -yl)dibenzo-[b,e][1,4]diazepine, and 2-chloro-11 -(4-methylpiperazin-1 -yl)dibenzo[b,e][1,4]diazepine monohydrate}. J. Chem. Soc. [Perkin II] 1976, 1415–1420Google Scholar
  88. Petersen, P.V., Møller-Nielsen, I., Pedersen, V., Jørgensen, A., Lassen, N.: Thioxanthenes. In: Psychotherapeutic drugs, Part II. Usdin, E., Forrest, I.S. (eds.), pp. 827–867. New York, Basel: Dekker 1977Google Scholar
  89. Posner, H.S., Hearst, E., Taylor, W.L., Cosmides, G.J.: Model metabolites of chlorpromazine and promazine: relative activities in some pharmacological and behavioral tests. J. Pharmacol. Exper. Therap. 137, 84–90 (1962)Google Scholar
  90. Pugsley, T.A., Lippmann, W.: Effects of chlorine substituents on the benzene rings of an analogue of the antipsychotic drug butaclamol on the interaction with dopamine and muscarinic receptors in rat brain. J. Pharm. Pharmacol. 31, 47–49 (1979)PubMedGoogle Scholar
  91. Pugsley, T.A., Merker, J., Lippmann, W.: Effect of structural analogs of butaclamol (a new antipsychotic drug) on striatal homovanillic acid and adenyl cyclase of olfactory tubercle in rats. Can. J. Physiol. Pharmacol. 54, 510–515 (1976)PubMedGoogle Scholar
  92. Rajšner, M., Metyšová, J., Svátek, E., Mikšík, F., Protiva, M.: 2- and 3-fluoro derivatives of clorotepin and related compounds; 6- and 7-fluoro derivatives of chlorprothixene. Coll. Czech. Chem. Commun. 40, 719–737 (1975)Google Scholar
  93. Reboul, J.-P., Cristau, B.: Analyse pharmacochimique des données fournies par la radiocristal-lographie des amines psychotropes polycycliques. I. Définition et calcul des paramètres conformationnels. Eur. J. Med. Chem. (Chim. Therap.) 12, 71–75 (1977 a)Google Scholar
  94. Reboul, J.-P., Cristau, B.: Analyse pharmacochimique des données fournies par la radiocristal-lographie des amines psychotropes polycycliques. II. Confrontation des valeurs paramétriques. Eur. J. Med. Chem. (Chim. Therap.) 12, 76–79 (1977 b)Google Scholar
  95. Reboul, J.P., Cristau, B.: Les amines psychotropes polycycliques «vues» par l’ordinateur. Annal. Pharm. Fr. 36, 179–189 (1978)Google Scholar
  96. Remy, D.C., Rittle, K.E., Hunt, C.A., Anderson, P.S., Arison, B.H., Engelhardt, E.L., Hirschmann, R., Clineschmidt, B.V., Lotti, V.J., Bunting, P.R., Ballentine, R.J., Papp, N.L., Flataker, L., Witoslawski, J.J., Stone, CA.: Synthesis and stereospecific antipsychotic activity of (—)-1-cyclopropylmethyl-4-(3-trifluoromethylthio-5H-dibenzo[a,d]cyclohepten-5-ylidene)piperidine. J. Med. Chem. 20, 1013–1019 (1977)PubMedGoogle Scholar
  97. Robinson, S.E., Lotti, V.J., Sulser, F.: Cyanocyproheptadine: role of cholinolytic properties in modulating neuroleptic-induced elevation of striatal homovanillic acid (HVA). J. Pharm. Pharmacol. 29, 564–566 (1977)PubMedGoogle Scholar
  98. Rodgers, J.R., Horn, A.S., Kennard, O.: Antipsychotic phenothiazine drugs and the significance of the X-ray structure of promazine HCl. J. Pharm. Pharmacol. 28, 246–247 (1976)PubMedGoogle Scholar
  99. Roufogalis, B.D., Thornton, ML, Wade, D.N.: Specificity of the dopamine-sensitive adenylate cyclase for antipsychotic antagonists. Life Sci. 19, 927–934 (1976)PubMedGoogle Scholar
  100. Sayers, A.C., Bürki, H.R., Ruch, W., Asper, H.: Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects. Psychopharmacol. 51, 15–22 (1976)Google Scholar
  101. Schmutz, J.: Absicht und Zufall in der Arzneimittelforschung, dargelegt am Beispiel der trizyklischen Psychopharmaka. Pharmacol. Acta Helv. 48, 117–132 (1973)Google Scholar
  102. Schmutz, J.: Neuroleptic piperazinyl-dibenzo-azepines. Chemistry and structure-activity relationships. Arzneim. Forsch. 25, 712–720 (1975)Google Scholar
  103. Schmutz, J., Hunziker, F., Stille, G., Lauener, H.: Constitution chimique et action pharma-cologique d’un nouveau groupe de neuroleptiques tricycliques. Bull. Chim. Thérap. 1967, 424–429Google Scholar
  104. Seeman, P., Lee, T., Chau-Wong, M., Wong, K.: Antipsychotic drugs and neuroleptic/dopamine receptors. Nature 261, 717–719 (1976)PubMedGoogle Scholar
  105. Šindelář, K., Jílek, J.O., Metyšová, J., Pomykáček, J., Protiva, M.: 2- and 3-hydroxy derivatives of 8-chloro-10-(4-methylpiperazino)-10, 11-dihydrodibenzo[b,f]thiepin and their methyl ethers. Coll. Czech. Chem. Commun. 39, 3548–3559 (1974)Google Scholar
  106. Šindelář, K., Dlabač, A., Kakáč, B., Svátek, E., Holubek, J., Šedivý, Z., Princová, E., Protiva, M.: Noncataleptic potential neuroleptics; 2-acetamido, 2-amino and 2-acetyl derivatives of 10-(4-methylpiperazino)-10, 11-dihydrodibenzo[b,f]thiepin. Coll. Czech. Chem. Commun. 40, 2649–2666 (1975 a)Google Scholar
  107. Šindelář, K., Dlabač, A., Metyšová, J., Kakáč, B., Holubek, J., Svátek, E., Šedivý, Z., Protiva, M.: Potential antipsychotics: 2-methoxy-, 2-methylthio-, 2-dimethylsulfamoyl- and 2-trifluoromethyl-10-piperazinodibenzo[b,f]thiepins. Coll. Czech. Chem. Commun. 40, 1940–1959 (1975 b)Google Scholar
  108. Šindelář, K., Metyšová, J., Holubek, J., Šedivý, Z., Protiva, M.: Potential oral neuroleptics with protracted action; 8-chloro-3, 7-difluoro-10-(4-methylpiperazino)-10, 11-dihydrodiben-zo[b,f]thiepin and further 3,7-substituted octoclothepin and dehydroclothepin derivatives. Coll. Czech. Chem. Commun. 42, 1179–1199 (1977)Google Scholar
  109. Snyder, S.H., Greenberg, D., Yamamura, H.I.: Antischizophrenic drugs and brain cholinergic receptors. Arch. Gen. Psychiatr. 31, 58–61 (1974)PubMedGoogle Scholar
  110. Stille, G., Lauener, H., Eichenberger, E.: The pharmacology of 8-chloro-ll-(4-methyl-l-piperazinyl)-5H-dibenzo[b,e][l,4]diazepine (clozapine). Farmaco. [Prat.] 26, 603–625 (1971)Google Scholar
  111. Ternay, L.A., Evans, S.A.: Stereochemistry and conformational preferences of meso-alkylated thioxanthenes by proton magnetic resonance spectroscopy. J. Org. Chem. 39, 2941–2946 (1974)Google Scholar
  112. Tollenaere, J.P., Moereels, H., Protiva, M.: Quantitative structure activity relationship (QSAR) in a series of neuroleptic 10-piperazino-dibenzo[b,f]thiepins, ataxia in mice. Eur. J. Med. Chem. (Chim. Therap.) 11, 293–298 (1976)Google Scholar
  113. Tollenaere, J.P., Moereels, H., Koch, M.H.J.: On the conformation of neuroleptic drugs in the three aggregation states and their conformational resemblance to dopamine. Eur. J. Med. Chem. (Chim. Therap.) 12, 199–211 (1977)Google Scholar
  114. Ueda, I., Sato, Y., Maeno, S., Umio, S.: Synthesis and pharmacological properties of 8-chloro-10-(2-dimethylamino-ethoxy)dibenz[b,f]thiepin and related compounds. Neurotropic and psychotropic agents III. Chem. Pharm. Bull. (Tokyo) 26, 3058–3070 (1978)PubMedGoogle Scholar
  115. Voith, K., Cummings, J.R.: Behavioral studies on the enantiomers of butaclamol demonstrating absolute optical specificity for neuroleptic activity. Can. J. Physiol. Pharmacol. 54, 551–560 (1976)PubMedGoogle Scholar
  116. Voith, K., Bruderlein, F.T., Humber, L.G.: Neuroleptics related to butaclamol. Synthesis and some psychopharmacological effects of a series of 3-aryl analogues. J. Med. Chem. 21, 694–698 (1978)PubMedGoogle Scholar
  117. Watzman, N., Manian, A.A., Barry, H., Buckley, J.P.: Comparative effects of chlorpromazine hydrochloride and quaternary chlorpromazine hydrochloride on the central nervous systems of rats and mice. J. Pharm. Sci. 57, 2089–2093 (1968)PubMedGoogle Scholar
  118. Wilhelm, M., Kuhn, R.: Versuch einer stereochemisch-strukturellen Klassifizierung der Trizy-klus-Psychopharmaka mit Einschluß der Dibenzobicyclooctadine. Pharmakopsychiatr. Neuropsychopharmakol. 3, 317–332 (1970)Google Scholar
  119. Yale, H.L.: The long-acting neuroleptics: A retrospective appraisal. Drug Metab. Rev. 8, 251–262 (1978)PubMedGoogle Scholar
  120. Yale, H.L., Beer, B., Pluscec, J., Spitzmiller, E.R.: Novel polycyclic heterocycles. Derivatives of 5,11-dihydrodibenz[b,e][1,4]oxazepine and 5,11-dihydrodibenzo[b,e][l,4]thiazepine. J. Med. Chem. 13, 713–722 (1970)PubMedGoogle Scholar
  121. Zirkle, C.L., Kaiser, C.: Antipsychotic agents (tricyclic). In: Psychopharmacological Agents. Gordon, M. (ed.). New York: Academic Press 1974, Vol. 3, pp. 39–128Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • J. Schmutz
  • C. W. Picard

There are no affiliations available

Personalised recommendations